Canada

BMI Core View: Uptake of generic drugs following patent expiry will become swifter. This trend will reduce costs for governments, out-of-pocket payers and insurance companies, which... 2012-09-13

BMI View: Valeant needs to monitor its high debt ratio and operational efficiency closely following its many acquisitions over the past five years. We expect the company to continue... 2012-09-05

BMI View: Canada's policy of supporting high drug prices in order to support national R&D should be reviewed, as the R&D spending to domestic revenue ratio has declined... 2012-07-03

BMI Core View: Telecare will generate significant revenues in both developed and emerging markets. Growth in the number of mobile phone users and wireless subscribers and advances in... 2012-06-22

BMI View: Patented medicine sales accounted for 62% of total Canadian pharmaceutical sales in 2011 and this subsector's share of total pharmaceutical sales (prescription drugs and over-the-counter... 2012-03-29

BMI View: Multinational pharmaceutical companies will face ongoing pricing pressure in Canada's generic drug sector due to impending legislation. Local pharmacies will take the brunt... 2012-03-05

BMI View: Canada's aging population, increasing demand for high-tech devices from healthcare professionals and comparatively healthy public finances will enable the medical device sector... 2012-02-13